Biomarkers predicting response to bevacizumab in patients with recurrent malignant glioma.
Phase of Trial: Phase IV
Latest Information Update: 25 Jun 2014
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioma
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 25 Jun 2014 New trial record
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.